Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Hosp Infect ; 103(3): 321-327, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31226271

ABSTRACT

BACKGROUND: Hand hygiene compliance even before infection-prone procedures (indication 2, 'before aseptic tasks', according to the World Health Organization (WHO)) remains disappointing. AIM: To improve hand hygiene compliance by implementing gloved hand disinfection as a resource-neutral process optimization strategy. METHODS: We performed a three-phase intervention study on a stem cell transplant ward. After baseline evaluation of hand hygiene compliance (phase 1) gloved hand disinfection was allowed (phase 2) and restricted (phase 3) to evaluate and differentiate intervention derived from learning and time effects. The incidence of severe infections as well as of hospital-acquired multidrug-resistant bacteria was recorded by active surveillance. FINDINGS: Hand hygiene compliance improved significantly from 50% to 76% (P < 0.001) when gloved hand disinfection was allowed. The biggest increase was for infection-prone procedures (WHO 2) from 31% to 65%; P < 0.001. Severe infections decreased by trend (from 6.0 to 2.5 per 1000 patient-days) whereas transmission of multidrug-resistant organisms was not affected. CONCLUSION: Gloved hand disinfection significantly improved compliance with the hand hygiene, especially in activities relevant to infections and infection prevention. Thus, this process optimization may be an additional, easy implementable, resource-neutral tool for a highly vulnerable patient cohort.


Subject(s)
Catheter-Related Infections/prevention & control , Catheterization/adverse effects , Cross Infection/prevention & control , Hand Disinfection/methods , Infection Control/methods , Stem Cell Transplantation/adverse effects , Bacteria/drug effects , Bacteria/isolation & purification , Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Drug Resistance, Multiple, Bacterial , Female , Guideline Adherence , Humans , Incidence , Male
2.
South Med J ; 79(6): 669-73, 1986 Jun.
Article in English | MEDLINE | ID: mdl-3086983

ABSTRACT

Optimal parenteral nutritional support, provided concomitantly with extraordinarily large replacement doses of intravenous iron dextran can be safe, effective, and life-saving for severely anemic patients who cannot or will not accept erythrocyte transfusion. Five patients who had sustained massive acute blood loss and two who had severe chronic anemia received as much as 140 ml of iron dextran intravenously. The average initial hemoglobin value in the patients with acute blood loss was 4.7 gm/dl (range 2.6 to 8.4 gm/dl), increasing to an average of 9.8 gm/dl (range 7.5 to 12.8) in 23.4 days (range 17 to 30 days), a 166% increase. The average initial hemoglobin value in the patients with chronic anemia was 3.7 gm/dl, increasing to 10.5 gm/dl over an average period of 121 days, a 182% increase. Total abdominal colectomy, pyloroplasty with truncal vagotomy, and highly selective vagotomy were accomplished without complications in four of the patients. There were no adverse reactions to the therapeutic regimen, and all patients were discharged in good condition.


Subject(s)
Anemia, Hypochromic/therapy , Hematopoiesis/drug effects , Iron-Dextran Complex/administration & dosage , Adult , Aged , Anemia, Hypochromic/etiology , Blood Transfusion , Chronic Disease , Evaluation Studies as Topic , Female , Gastrointestinal Hemorrhage/complications , Hemoglobins/analysis , Humans , Iron-Dextran Complex/adverse effects , Male , Middle Aged , Parenteral Nutrition, Total , Time Factors
3.
Arch Surg ; 120(6): 721-7, 1985 Jun.
Article in English | MEDLINE | ID: mdl-3924007

ABSTRACT

Optimal parenteral nutritional support, concomitant with replacement doses of intravenous iron dextran injection, can be safe, effective, and lifesaving for severely anemic patients who are unable to receive blood transfusions. Six patients who had sustained massive acute blood loss and two who had severe chronic anemia received as much as 140 mL of iron dextran injection intravenously. The average initial hemoglobin level in the acute group was 5.0 g/dL (range, 2.6 to 8.4 g/dL) and increased to an average of 10.6 g/dL (range, 7.5 to 12.8 g/dL) in 23 days (range, 17 to 30 days); the hemoglobin level in the chronic group was 3.8 g/dL and increased to 10.6 g/dL over an average period of 121 days. Two total abdominal colectomies, a right transverse colectomy and fistulectomy, a pyloroplasty and vagotomy, and a highly selective vagotomy were accomplished without complications in five of the patients. There were no adverse reactions to the hematopoietic therapy.


Subject(s)
Anemia/therapy , Blood Transfusion , Erythrocyte Volume/drug effects , Erythropoiesis/drug effects , Gastrointestinal Diseases/surgery , Iron-Dextran Complex/therapeutic use , Patient Compliance , Adult , Aged , Anemia/blood , Anemia/etiology , Female , Gastrointestinal Diseases/complications , Hemoglobins/analysis , Humans , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/pharmacology , Male , Middle Aged , Parenteral Nutrition, Total
SELECTION OF CITATIONS
SEARCH DETAIL
...